Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

被引:132
作者
Hesketh, Paul J. [1 ]
Aapro, Matti [2 ]
Street, James C. [3 ]
Carides, Alexandra D. [4 ]
机构
[1] St Elizabeths Med Ctr, Brighton, MA 02135 USA
[2] Clin Genolier, Inst Multidisciplinaire Oncol, Genolier, Switzerland
[3] Reagent, New York, NY 10011 USA
[4] Merck Res Labs, West Point, PA 19486 USA
关键词
Aprepitant; Chemotherapy; Cisplatin; Emesis; Risk factor; PLACEBO-CONTROLLED TRIAL; ANTAGONIST APREPITANT; DOUBLE-BLIND; INDUCED EMESIS; PREVENTION; CANCER; ONCOLOGY;
D O I
10.1007/s00520-009-0737-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Certain patient and treatment characteristics are predictive of chemotherapy-induced nausea and vomiting (CINV). Objectives of this analysis were: (1) confirm the importance of several previously reported adverse risk factors for CINV in patients receiving chemotherapy, (2) assess the impact of the NK(1) receptor antagonist aprepitant according to these risk factors, and (3) assess the impact of age on antiemetic outcome. Patients from two double-blind, placebo-controlled trials were randomized to an active-control group (ondansetron 32 mg IV, dexamethasone 20 mg PO day 1; dexamethasone 8 mg bid days 2-4) or an aprepitant group (aprepitant 125 mg PO, ondansetron 32 mg IV, dexamethasone 12 mg day 1; aprepitant 80 mg days 2-3; dexamethasone 8 mg qd days 2-4). The primary endpoint was complete response (no emesis or rescue therapy use). In a post-hoc analysis, multivariate logistic regression models were used to assess the impact of treatment with aprepitant and previously reported risk factors, using a modified intent-to-treat approach. Treatment with aprepitant (p < 0.0001), male gender (p = 0.023), cisplatin dose < 80 mg/m(2) (p = 0.001), age a parts per thousand yen65 years (p = 0.021), and five or more alcoholic drinks per week (p = 0.027) were all significantly associated with improved complete response. Aprepitant improved complete response regardless of risk for all factors and neutralized the risk associated with female gender. This analysis confirmed the relevance of several previously reported risk factors for CINV in patients receiving chemotherapy. Aprepitant improved complete response regardless of risk and eliminated the increased risk of CINV associated with the female gender.
引用
收藏
页码:1171 / 1177
页数:7
相关论文
共 18 条
[1]  
Booth Christopher M, 2007, J Support Oncol, V5, P374
[2]  
D'ACQUISTO R, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P257
[3]   Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis [J].
Herrstedt, J. ;
Roila, F. .
ANNALS OF ONCOLOGY, 2008, 19 :110-112
[4]  
Hesketh P J, 1999, Oncologist, V4, P191
[5]   The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group [J].
Hesketh, PJ ;
Grunberg, SM ;
Gralla, RJ ;
Warr, DG ;
Roila, F ;
De Wit, R ;
Chawla, SP ;
Carides, AD ;
Ianus, J ;
Elmer, ME ;
Evans, JK ;
Beck, K ;
Reines, S ;
Horgan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4112-4119
[6]  
HESKETH PJ, 1992, MECH CONTROL EMESIS, P25
[7]   American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 [J].
Kris, Mark G. ;
Hesketh, Paul J. ;
Somerfield, Mark R. ;
Feyer, Petra ;
Clark-Snow, Rebecca ;
Koeller, James M. ;
Morrow, Gary R. ;
Chinnery, Lawrence W. ;
Chesney, Maurice J. ;
Gralla, Richard J. ;
Grunberg, Steven M. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2932-2947
[8]   Determinants of postchemotherapy nausea and vomiting in patients with cancer [J].
Osoba, D ;
Zee, B ;
Pater, J ;
Warr, D ;
Latreille, J ;
Kaizer, L .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :116-123
[9]   Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting - Results from a randomized, double-blind, placebo-controlled trial in Latin America [J].
Poli-Bigelli, S ;
Rodrigues-Pereira, J ;
Carides, AD ;
Ma, GGJ ;
Eldridge, K ;
Hipple, A ;
Evans, JK ;
Horgan, KJ ;
Lawson, F .
CANCER, 2003, 97 (12) :3090-3098
[10]  
POLLERA CF, 1989, CANCER-AM CANCER SOC, V64, P1117, DOI 10.1002/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO